Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemvidutide (ALT-801) in NAFLD
NCT05006885Phase 1Completed
- Sponsor
- Altimmune, Inc.
- Start
- Sep 2021
- Primary completion
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pemvidutide in non-alcoholic fatty liver disease (NAFLD) (4 arms), sponsored by Altimmune, Inc. Primary endpoint: Number of Participants with One or More Treatment-Emergent Adverse Events at Day 110. Started Sep 2021; status: completed.
02
Drugs
pemvidutide
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05006885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05006885.